Evidence map›Paper›PMID 35004217›Full record

ArticleMethodsX2021

The concentration of brain homogenates with the Amicon Ultra Centrifugal filters.

Joshua Yang, Rachita K Sumbria

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MethodsX, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Joshua YangHenry E. Riggs School of Applied Life Sciences, Keck Graduate Institute, Claremont, CA 91711, USA.
Rachita K SumbriaDepartment of Biomedical and Pharmaceutical Sciences, School of Pharmacy, Chapman University, Irvine, CA 92618, USA.
Chapman University · USKeck Graduate Institute · US

Funding

A Brain Penetrating Bi-functional Transferrin Receptor Antibody-TNF-alpha Decoy Receptor Fusion Protein for Alzheimer's DiseaseR01AG062840 · NIA · KECK GRADUATE INST OF APPLIED LIFE SCIS · PI SUMBRIA, RACHITA · 2019 to 2024
$1.9M
Re-engineering Erythropoietin for Alzheimer's DiseaseR21AG055949 · NIA · KECK GRADUATE INST OF APPLIED LIFE SCIS · PI SUMBRIA, RACHITA · 2017 to 2018
$382k
NIA NIH HHS R01 AG062840NIA NIH HHS R21 AG055949
6 · The paper itself

Abstract

Accurately measuring the brain concentration of a neurotherapeutic is critical in determining its pharmacokinetic profile

Indexed as

(Asn), Asparagine(BBB), Blood-Brain BarrierBlood-Brain Barrier (BBB)Brain concentration(CNS), Central Nervous System(cTfRMAb), Chimeric Monoclonal Antibody Targeting the Mouse Transferrin Receptor(ELISA), Enzyme-Linked Immunosorbent AssayEnzyme-linked immunosorbent assay (ELISA)(EPO), Erythropoietin(EPOR), EPO Receptors(Gly), Glycine(PBS), Phosphate Buffered SalinePharmacokinetics(SEM), Standard Error of the Mean(TBS), Tris Buffered Saline(T-PER), Tissue Protein Extraction Reagent

Identifiers

PMID35004217
PMCPMC8720913
OpenAlexW3213806304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.